Daktronics approved a manufacturing network optimization plan involving the phased-exit of its Ennistymon, Ireland facility and the highly customized international transportation business. The restructuring is expected to result in $13.5 million in cumulative charges but generate $18.0 million in annualized pre-tax savings by fiscal 2028. The company also corrected a clerical error in its previous 10-Q filing, updating its fiscal 2027 capital expenditure projection from $13.2 million to $23.4 million.
Oncolytics Biotech provided an operational update on its GOBLET Phase 1/2 study, announcing the completion of enrollment and the expected receipt of a final grant payment from the Pancreatic Cancer Action Network (PanCAN). The company expects to report final results from Cohort 4 in Q4 2026 and initial results from Cohort 5 in the first half of 2027.
Eagle Point Credit Company provided preliminary unaudited estimates for the period ended September 30, 2026, including a net asset value (NAV) per common share between $4.12 and $4.22. The company also estimated net investment income and realized losses between $0.27 and $0.31 per weighted average common share for the third quarter.
Eagle Point Income Company provided preliminary unaudited estimates for the quarter ended September 30, 2026. The company estimated its net asset value (NAV) per common share to be between $12.34 and $12.44, and its net investment income (NII) and realized losses to be between $0.65 and $0.69 per weighted average common share.
Coya Therapeutics announced plans to initiate an open-label extension for its Phase 2/3 ALSTARS trial of COYA 302 in ALS to collect long-term safety and efficacy data. Due to resource prioritization for the ALS program, the company has delayed the planned initiation of its Phase 2 trial for COYA 302 in frontotemporal dementia from late 2026 to 2027.
Datacentrex has begun the installation and energization of over 500 additional ElphaPex DG2 Scrypt ASIC miners, which were previously acquired and prepaid. Upon full deployment, the company expects its online Scrypt hashrate to increase by approximately 21% to 52.2 TH/s and its total power capacity to reach 14 MW. This expansion brings the company's total fleet to more than 3,500 miners across four U.S. colocation facilities.
Valion Bio highlighted the capabilities of its wholly owned CDMO subsidiary, Velocity Bioworks, to support biotechnology companies seeking domestic U.S.-based manufacturing. The update follows the implementation of Section 232 pharmaceutical tariffs, positioning Velocity's San Antonio facility as a strategic option for early-phase clinical drug substance manufacturing.
MaxCyte announced preliminary Q3 2026 core business revenue of approximately $8.1 million, a 26% year-over-year increase. The company also raised its full-year 2026 total revenue guidance to approximately $34 million, up from the previous range of $30 million to $32 million, driven by accelerated instrument purchasing and milestone payments.
Range Resources Corporation provided preliminary estimates for its derivative settlements for the third quarter ended September 30, 2026. The company expects to report a total gain on derivatives of $58.1 million and total net cash receipts on derivative settlements of approximately $51.9 million.
Eagle Nuclear Energy provided a corporate update for the third quarter of 2026, highlighting progress at its Aurora Uranium Project and its Small Modular Reactor (SMR) technology platform. The company has engaged technical contractors for an upcoming drill program and expects to complete a Pre-Feasibility Study (PFS) at Aurora in the second half of 2027, pending state regulatory permits. Additionally, the company noted its recent inclusion in major uranium-focused ETFs, including the Global X Uranium ETF.
First Breach announced an expanded recruitment initiative to support increased ammunition production and the planned buildout of drone manufacturing operations in Hagerstown, Maryland. Additionally, the company reported that its proprietary drone prototype completed its first autonomous flight, marking a milestone in its flight software development partnership with Hellbender, Inc.
Pearl Diver Credit Company Inc. disclosed its unaudited net asset value (NAV) per share of common stock, which was $10.67 as of September 30, 2026. This filing provides a routine monthly or quarterly operational update on the company's asset value for investors.
Hycroft Mining announced results from its 2025-2026 Exploration Drill Program, including the highest-grade gold intercept in the company's 40-year history. Hole H26D-6175A at the Vortex system returned 19.6 meters at 30.49 g/t gold and 1,726.72 g/t silver, suggesting proximity to a potential source of the mineralization system.
EQT Corporation provided preliminary financial metrics for the third quarter of 2026, specifically regarding its derivative positions. The company expects to report a total gain on derivatives of $100 million and net cash settlements received on derivatives of $70 million for the period ended September 30, 2026.
Better Home & Finance reported preliminary Q3 2026 loan volume of $1.39 billion, a 15% year-over-year increase despite a 37% decline in industry volume. The company also launched a 'Better 2.0' scorecard, implementing $13 million in annualized expense reductions with a target of an additional $51 million in reductions over the next four weeks to reach Adjusted EBITDA breakeven.
Arrive AI announced the formation of Arrive AI Defense, a new division focused on bringing its autonomous delivery infrastructure to the military, defense, and national security sectors. Led by Chief Strategy Officer Neerav Shah, the division will pursue government contracting and non-dilutive funding opportunities for applications like autonomous battlefield resupply and secure logistics at U.S. embassies.
Palmer Square Capital BDC Inc. provided an unaudited estimate of its net asset value (NAV) per share. As of September 30, 2026, the company's estimated NAV per share was $13.34.
Flyte Aviation reported record preliminary Q3 2026 revenue of $2.15 million, a 110% sequential increase from Q2 2026. The growth was driven by a 150% sequential increase in aviation segment revenue and a 185% surge in its digital platform user base following a May 2026 redesign.
Victory Capital reported total client assets of $355.5 billion as of September 30, 2026, including $351.9 billion in assets under management (AUM). The company also disclosed long-term AUM net inflows of $11.7 billion for the third quarter of 2026.
SS Innovations International submitted its response to the FDA's request for additional information regarding its 510(k) application for the SSi Mantra surgical robotic system. The response includes final data from expanded human clinical and human factors validation studies, with a final FDA review decision anticipated in the first quarter of 2027.
Bluejay Diagnostics achieved a critical contractual milestone under its license agreement with Toray Industries by establishing a manufacturing site for its Symphony cartridges at SanyoSeiko Co. in Japan. This milestone was reached ahead of the October 23, 2026 deadline and is part of a broader strategy to build a resilient supply chain alongside its U.S. manufacturing partner, ALURIS Sciences.
DeFi Development Corp. reported that its treasury holdings of SOL and SOL equivalents grew by 22,070 tokens over a one-week period, reaching a total of 2,586,282 SOL. The company highlighted that its SOL holdings have increased by 12% since August 12, 2026, and noted that its CHAD preferred stock reached record highs despite broader crypto market volatility.
Bitmine Immersion Technologies provided an operational update disclosing total crypto, cash, and marketable securities holdings of $16.2 billion. The company's holdings include 6.03 million ETH tokens, representing 4.9% of the total ETH supply, and 214 Bitcoin, alongside significant stakes in Beast Industries and Eightco Holdings.
Phio Pharmaceuticals successfully completed its first commercial-scale cGMP batch of PH-762 drug substance, a key manufacturing milestone. This achievement validates the company's supply chain readiness and supports the planned initiation of a Phase 2b clinical trial in the first quarter of 2027.
Runway Growth Finance Corp. provided a portfolio update for the quarter ended September 30, 2026, reporting $8.5 million in follow-on fundings across four existing portfolio companies. The company also experienced significant liquidity events totaling $139.4 million, driven by full repayments from 3PL Central, Route 92 Medical, Onward Medical, and Shepherd Intermediate.
California Resources Corp provided preliminary Q3 2026 operational data, reporting realized oil prices of $83.42 per barrel before derivative settlements and $72.46 after settlements. The company also estimated a $134 million loss from net settlement of commodity derivatives for the quarter. Management noted that current oil price realizations relative to Brent are not considered a long-term run rate and expects improvements from ongoing commercial and logistics actions.
Oncolytics Biotech provided an update on its intellectual property strategy, including the issuance of new method of use patents for pelareorep in several countries and plans for a 'next generation' composition of matter patent. The company aims to extend its patent protection into the late 2040s, building on existing manufacturing protection that currently runs through 2044.
Strive, Inc. announced it purchased 3,311 bitcoin between October 5 and October 9, 2026, at an average price of approximately $84,500 per bitcoin. The company also provided a weekly update on its treasury holdings, reporting a total of 32,773 bitcoin and $310.3 million in cash and cash equivalents as of October 9, 2026.
Super League Enterprise, Inc. announced an inaugural purchase of one Bitcoin for $83,041.40. The company is exploring Bitcoin as a treasury asset to be held alongside its cash and cash equivalents.
Mesa Laboratories approved a restructuring program to reduce annualized operating costs by approximately $9.3 million, primarily by focusing its Clinical Genomics division on pharmacogenomics and oncology. The plan involves eliminating 40 positions (6% of the workforce) and exiting a facility in Hamburg, Germany, with an estimated $2.6 million to $3.4 million in pre-tax charges.